Chih-Yao Yang

Title: The Innovative Mind of Chih-Yao Yang: A Focus on Sustained Release Oral Dosage Form

Introduction: Chih-Yao Yang, an accomplished inventor based in New Taipei, Taiwan, has made significant strides in the pharmaceutical field. His innovation is encapsulated in a patent that addresses the delivery of dalfampridine, a medication that plays a crucial role in enhancing mobility. With a keen understanding of drug formulation, Yang has developed a solution that offers a once-daily dosage method.

Latest Patents: Yang's sole patent is titled "Sustained release oral dosage form containing dalfampridine." This innovation is designed to ensure that patients receive a consistent dose of the drug while minimizing potential side effects. The oral dosage form incorporates osmotic agents within a tablet core, allowing for controlled release. This mechanism not only prevents alcohol-induced dose dumping but also maintains a steady plasma concentration of the drug throughout the day.

Career Highlights: Chih-Yao Yang is currently associated with Pharmadax Inc., a company known for its commitment to advancing pharmaceutical technologies. His work at Pharmadax reflects a dedication to improving patient outcomes through innovative medication administration.

Collaborations: Throughout his career, Yang has worked alongside notable colleagues such as Jen-Sen Wu and Shih-Wei Huang. This collaboration has facilitated a productive environment for research and development, strengthening the impact of their collective work in the pharmaceutical industry.

Conclusion: Chih-Yao Yang stands out as a significant figure in the realm of pharmaceutical innovation. His patent for a sustained release oral dosage form of dalfampridine illustrates his expertise and commitment to improving drug delivery systems. Through his contributions at Pharmadax Inc., Yang continues to influence the future of medicine, underscoring the importance of innovation in enhancing patient care.